Table 1 Patient and treatment characteristics.
Characteristic | All patients | < 66 Gy group | ≥ 66 Gy group | p-value |
|---|---|---|---|---|
Total | n = 292 | n = 66 | n = 226 | |
Age at SRT (year) | 68 (49–80) | 70 (52–77) | 68 (49–80) | 0.22 |
Gleason score | 0.013 | |||
≤ 6 | 30 (10%) | 11 (17%) | 19 (8.4%) | |
7 | 161 (55%) | 41 (62%) | 120 (53%) | |
8–10 | 101 (35%) | 14 (21%) | 87 (39%) | |
T stage | 0.68 | |||
≤ pT2c | 159 (55%) | 38 (58%) | 121 (54%) | |
pT3a | 88 (30%) | 17 (26%) | 71 (31%) | |
pT3b | 45 (15%) | 11 (17%) | 34 (15%) | |
ECE + | 123 (42%) | 23 (35%) | 100 (44%) | 0.20 |
SVI + | 45 (15%) | 11 (17%) | 34 (15%) | 0.70 |
Surgical margin + | 172 (59%) | 33 (50%) | 139 (62%) | 0.12 |
Preoperative initial PSA (ng/ml) | 11.4 (4.00–84.1) | 10.8 (4.00–56.9) | 11.7 (4.18–84.1) | 0.59 |
Postoperative PSA nadir (ng/ml) | 0.04 (0.00–1.82) | 0.06 (0.00–1.74) | 0.04 (0.00–1.82) | 0.83 |
PSA at BCR after RP (ng/ml) | 0.38 (0.10–1.94) | 0.32 (0.10–1.94) | 0.42 (0.10–2.00) | 0.012 |
EQD2 (Gy) | 66.0 (61.0–85.0) | 64.0 (61.0–65.0) | 67.0 (66.0–85.0) | < 0.001 |
WPRT | 11 (4%) | 2 (3%) | 9 (4%) | 1.0 |
Short-term ADT use with SRT | 16 (6%) | 2 (3%) | 14 (6%) | 0.54 |
Follow-up time (month)a | 73 (5–189) | 98 (11–166) | 68 (5–189) | 0.001 |
2006–2013 | n = 131 | n = 54 | n = 77 | |
102 (6–189) | 114 (11–166) | 100 (6–189) | 0.25 | |
2014–2018 | n = 161 | n = 12 | n = 149 | |
60 (5–97) | 55 (23–92) | 61 (5–97) | 0.42 | |
Total | n = 118 | n = 23 | n = 95 | |
PSA at BCR after SRT (ng/ml) | 0.30 (0.01–4.32) | 0.35 (0.21–3.21) | 0.30 (0.01–4.32) | 0.24 |
ADT use in patients with recurrence after SRT | 99 (84%) | 21 (91%) | 78 (82%) | 0.36 |
